Drug Testing for Residual Progression of Diabetic Kidney Disease in Mice Beyond Therapy with Metformin, Ramipril, and Empagliflozin.

Manga MotrapuMonika Katarzyna ŚwiderskaIrene MesasJulian Aurelio MarschnerYutian LeiLaura Martinez ValenzuelaJia Fu Kyung LeeMaria Lucia AngelottiGiulia AntonelliPaola Romagnani Hans-Johachim AndersLidia Anguiano

Published in: Journal of the American Society of Nephrology : JASN (2020)

Add-on treatment with BIO for only 4 weeks attenuates progression of CKD beyond MRE therapy in mice with type 2 diabetes. Additional drug combinations may help to further delay ESKD in type 2 diabetes.

Keyphrases

type diabetes
high fat diet induced
chronic kidney disease
cardiovascular disease
stem cells
glycemic control
adipose tissue
replacement therapy
weight loss